Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

Contact
Request a demo
Request data updates
Add a company

Research

Companies
Investors
People

aVenture

Sitemap
Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage

Loading

Loading

Kim Kamdar

AddedMar 31, 2024

UpdatedMay 31, 2026

Kim Kamdar

Kim Kamdar

Board Member, Sera Prognostics

Kim Kamdar's Career

Sera Prognostics

Sera Prognostics

Salt Lake City, UT, US

Board Member· Board

Pleno

San Diego, CA, US

Board Member· Board

Seraphina Therapeutics

Seraphina Therapeutics

San Diego, CA, US

Board Member· Board

Rox Medical

San Clemente, CA, US

Board Member· Board

Adastra Pharmaceuticals

Adastra Pharmaceuticals

San Diego, CA, US

Board Member· Board

Truvian

San Diego, CA, US

Board Member· Board

Epic Sciences

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview

aVenture product preview

aVenture product preview

Kim Kamdar's Career

Sera Prognostics

Sera Prognostics

Public$245.6M1132008Salt Lake City, UT, US

Board Member· Board

Leadership at Sera Prognostics

Steve BorstCo-Founder

Jane F. BarlowBoard Member

Dennis FarrarBoard Member

Arnie OronskyBoard Member

Evguenia LindgardtCEO

Marcus WilsonBoard Member

Pleno

Series A$55M622017San Diego, CA, US

Board Member· Board

Leadership at Pleno

Pieter van RooyenFounder

Greg LucierBoard Member

Similar to Pleno

Singular GenomicsSan Diego, CA, USGenomic Technologiesest. 2016Singular GenomicsSan Diego, CA, US · est. 2016

Singular Genomics: A dynamic, fast-paced biotech company in California, innovating in genomic technologies.

Public · $176M134

Nest GenomicsNew York City, NY, USGenomics Softwareest. 2022Nest GenomicsNew York City, NY, US · est. 2022

Nest Genomics: Comprehensive genomic software for clinical care integration and management.

OmniVisSouth San Francisco, CA, USDiagnostics, Pathogen Detectionest. 2017OmniVisSouth San Francisco, CA, US · est. 2017

OmniVis: A leading biotech startup revolutionizing pathogen detection with fast, accurate, and affordable handheld devices.

Series A · $3.5M5

Paragon GenomicsHayward, CA, USGenomic Testingest. 2015Paragon GenomicsHayward, CA, US · est. 2015

US-based Paragon Genomics, founded in 2016, provides diverse business services.

Series A · $8M22

Seraphina Therapeutics

Seraphina Therapeutics

Series A$5.5M52017San Diego, CA, US

Board Member· Board

Leadership at Seraphina Therapeutics

Stephanie VennFounder

Rox Medical

Series E$96.7M112004San Clemente, CA, US

Board Member· Board

Leadership at Rox Medical

David McIntyreBoard Member

Guido NeelsBoard Member

Rodney BrennemanFounder

Jon WaldstreicherBoard Member

Similar to Rox Medical

Rodo MedicalSunnyvale, CA, USDental Devicesest. 2009Rodo MedicalSunnyvale, CA, US · est. 2009

RODO Medical: Innovative dental device company offering the unique RODO Abutment System.

Pre-Seed · $7.7M17

Rotech HealthcareDavie, FL, USMedical Equipment, Medical Servicesest. 2002Rotech HealthcareDavie, FL, US · est. 2002

Rotech Healthcare: Providing home-based medical equipment and services for patient care.

Series A · $6.5M92

PulmonxRedwood City, CA, USMedical Devicesest. 1998PulmonxRedwood City, CA, US · est. 1998

Pulmonx Corp., based in Redwood City, US, globally develops and markets medical devices for pulmonary disorders.

Public · $276.9M269

Rockwell MedicalWixom, MI, USPharmaceuticalsest. 1995Rockwell MedicalWixom, MI, US · est. 1995

Rockwell Medical: A Michigan-based pharmaceutical company specializing in renal disease treatments since 1996.

Public · $100M253

Adastra Pharmaceuticals

Adastra Pharmaceuticals

Acquired$85M02005San Diego, CA, US

Board Member· Board

Leadership at Adastra Pharmaceuticals

Dennis PodlesakBoard Member

Ralph ChristoffersenBoard Member

Chris ChristoffersenBoard Member

Alain SchreiberBoard Member

Eckard WeberBoard Member

Chris LeMastersFounder

Similar to Adastra Pharmaceuticals

Adhera TherapeuticsDurham, NC, USPharmaceuticalsest. 1983Adhera TherapeuticsDurham, NC, US · est. 1983

US-based Adhera Therapeutics develops specialty pharmaceuticals for inflammatory diseases, hypertension, and cancer.

Seed · $3.2M37

Adventris PharmaceuticalsSan Francisco, CA, USCancer Vaccinesest. 2022Adventris PharmaceuticalsSan Francisco, CA, US · est. 2022

Adventris Pharmaceuticals, a San Francisco-based firm, specializes in developing cancer vaccines.

Pre-Seed · $500k6

Novita PharmaceuticalsNew York City, NY, USCancer Drugsest. 2010Novita PharmaceuticalsNew York City, NY, US · est. 2010

Novita Pharmaceuticals: Developing and providing cancer-treatment drugs since 2010, based in New York.

Series A · $8.5M7

Truvian

Series C$134.1M1282015San Diego, CA, US

Board Member· Board

Leadership at Truvian

Jean-Pierre MillonBoard Member

Paul MeisterBoard Member

Randal (Randy) ErmanCo-Founder

Megh GuptaBoard Member

Ashok KrishnamurthiBoard Member

Jay SrinivasanCEO

Epic Sciences

Series G$219.5M1142008San Diego, CA, US

Board Member· Board

Leadership at Epic Sciences

Evgeny ZaytsevBoard Member

Richard EglenBoard Member

James RothmanBoard Member

Murali PrahaladBoard Member

Peter KuhnFounder

Andrew ElbardissiBoard Member

Similar to Epic Sciences

Epi OneNew York City, NY, USCancer Diagnosticsest. 2016Epi OneNew York City, NY, US · est. 2016

Revolutionary cancer diagnosis platform for early prognosis, detection, and drug response.

Series B · $22.9M36

EpinomaSan Francisco, CA, USCancer Diagnosticsest. 2020EpinomaSan Francisco, CA, US · est. 2020

Innovative diagnostics company using multi-omics for cancer monitoring. Founded in 2020, based in San Francisco.

Pre-Seed · $125k6

OnCirc DiagnosticsBeverly Hills, CA, USCancer Diagnosticsest. 2009OnCirc DiagnosticsBeverly Hills, CA, US · est. 2009

Innovative cancer diagnostics biotech in Beverly Hills.

Pre-Seed · $500k30

Exact SciencesMadison, WI, USCancer Diagnosticsest. 1995Exact SciencesMadison, WI, US · est. 1995

Exact Sciences Corp., a US-based firm, develops non-invasive tests for early colorectal cancer detection.

Public · $2.1B6.4k

Kim Kamdar's Similar Executives & Operators

Jay Geoffrey WacherBoard Member · Bukalapak

Soemantri BrodjonegoroBoard Member · Bukalapak

Lau Eng BoonBoard Member · Bukalapak

WILL WEI CHENGBoard Member · DiDi

Dhirubhai H. AmbaniBoard Member · Reliance Retail

Mason YeoBoard Member · Kakao

JaeHong ChoiBoard Member · Kakao

Yun SeokBoard Member · Kakao

People Similar to Kim Kamdar

Steven GravesBoard Member · Sera Prognostics

Sean EsplinBoard Member · Sera Prognostics

J. Milton HarrisCo-Founder · Serina Therapeutics